Articles tagged with Ovarian Tumors
A preclinical study using a molecularly targeted treatment has successfully shrunk large majority of neurofibromas in mice with Neurofibromatosis 1 (NF1). The treatment, PD0325901, blocked MEK protein signaling, reducing tumor growth and feeding blood vessels.
Researchers at IDIBELL and ICO have developed new animal models for cancer research, including orthotopic implants of human tumor tissues in mice. These models mimic the growth of human tumors and response to chemotherapy, paving the way for personalized medicine against various cancers.
A recent study reveals that basal-like breast tumors and ovarian tumors have similar genetic origins, suggesting potential for shared treatments. The research found unique genetic signatures within each subtype, highlighting the need for personalized cancer therapies.
MIT researchers have developed RNA-delivering nanoparticles that allow for rapid screening of new drug targets in mice. These nanoparticles target the ID4 protein, shrinking ovarian tumors in their first mouse study. The technology has the potential to relieve a significant bottleneck in cancer-drug development.
The study discusses the biology of tumor-derived microvesicles and their clinical application as circulating biomarkers. Microvesicles released by tumor cells may provide a unique biosignature for individual cancers, enabling early detection and targeted therapies.
Researchers have created a universal approach to personalized cancer therapy based on T cells, offering a highly adaptable and effective treatment option. The system uses engineered T cells capable of targeting multiple tumor antigens simultaneously or sequentially, significantly extending conventional CAR approaches.
Researchers discovered that reduced expression of OGFr accelerates tumorigenesis in human ovarian cancer. The OGF-OGFr axis plays a fundamental role in regulating cell proliferation.
A new model of aggressive ovarian cancer reveals that dendritic cells actively support tumor progression, but can be restored to suppress it. Researchers propose targeting dendritic cells to control metastatic ovarian cancer.
The USP15 protein has been identified as a critical regulator of cancer progression and immune response, accelerating drug development against glioblastoma and other types of cancer. USP15 promotes tumor growth by activating the TGFβ pathway, but its inhibition can lead to decreased TGFβ activity and reduced tumor development.
A study by Wayne State University School of Medicine researchers found that targeted tumor freezing therapy increases ovarian cancer survival rates, with a 56-month average survival rate reported in 98% of patients. The treatment, called cryoablation, has been shown to be cost-effective, saving an average of $26,806 per life year.
Researchers analyzed tumor specimens from 19 advanced stage carcinoma patients, discovering changes in biomarker expression that may impact therapy selection for women with recurrent ovarian cancer. The study highlights the importance of analyzing current tumor tissue to make informed treatment decisions.
Researchers discuss management of cervical cancer during pregnancy, focusing on tumour size, nodal staging, term of pregnancy, and histological subtype. Chemotherapy can be used in the second or third trimester to increase chances of fetal preservation, but carries risks of premature birth and low birthweight.
A new study from the University of Hawaii Cancer Center found that PEA-15 protein enhances tumor formation in kidney cells carrying a mutation in the cancer-promoting gene H-Ras. The discovery suggests caution in pursuing PEA-15 as an anti-cancer therapeutic, highlighting its dual role in cancer growth and suppression.
Researchers at University of Guelph discovered a peptide that regresses established late-stage tumours in mouse models of ovarian cancer, improving survival rates. The peptide enhances chemotherapy drug delivery, allowing for lower doses and reduced side effects.
A new mathematical model developed by Stanford University scientists can help guide attempts to improve blood-based tumor detection methods. The model predicts that tumors can grow for 10 years or longer before detection using current blood tests, but may allow early detection within a shorter timeframe with the right biomarker.
Women undergoing IVF treatment have a higher risk of developing borderline ovarian tumours and an increased risk of malignant ovarian cancer compared to those not treated with IVF. The long-term risks are significant enough to warrant further research.
Women with high-grade ovarian cancer who have BRCA2 genetic mutations live longer and respond better to platinum-based chemotherapy. The tumors are more vulnerable to DNA-damaging agents, which could lead to effective treatment combinations.
A recurrent gene fusion between ESRRA and C11orf20 was found in about 15% of serous ovarian cancer cases, suggesting a potential marker for early detection. The discovery sheds light on how these deadly tumors develop and spread.
A new multispectral fluorescence imaging system has been developed to localize cancer cells during surgery, enabling surgeons to detect small clusters of tumor cells that might otherwise go undetected. In a study on nine patients with ovarian cancer, the system successfully detected and removed all cancer cells in eight cases.
A phase 2 trial found that olaparib reduced tumor size in 41% of patients with ovarian cancer and no BRCA gene mutations. The treatment was generally well-tolerated and offered new hope for ovarian cancer treatment targeting DNA repair mechanisms.
Research from the University of Pennsylvania suggests that ovarian cancer cells secrete chemical signals suppressing the immune system while promoting blood vessel growth. This discovery could lead to more effective cancer treatments by combining therapies targeting angiogenesis with those blocking immunosuppressive T-reg cells.
The study provides a comprehensive view of cancer genes for any cancer type to date, identifying patterns in gene expression that predict patient survival. The results support four distinct subtypes of the disease based on genomic changes and highlight potential therapeutic targets using existing drugs.
A new study suggests that the soy-based compound Natural S-equol does not increase the risk of estrogen-sensitive breast cancer. Supplements containing SE5-OH have reduced menopause symptoms in postmenopausal women, and the study's findings enhance our understanding of Natural S-equol's safety profile.
Researchers at Dana-Farber Cancer Institute found that 50 percent of young girls with Stage 1 germ cell ovarian tumors can be spared chemotherapy using a 'watch and wait' strategy. The treatment approach was effective in delaying recurrence and maintaining a survival rate of 96%.
Researchers found that EZH2 promotes tumor growth by shutting down genes that block formation of new blood vessels. Silencing EZH2 in ovarian cancer tumors reduced average tumor weight by 62% and increased programmed death of tumor cells.
A study analyzed the probability of surviving nine types of cancer in Spain, comparing rates to European averages. The results show varying survival rates for different cancers, with some types having high recovery rates (e.g., testicular and skin melanoma) while others have lower rates (e.g., lung cancer).
Women who have had a bilateral oophorectomy tend to have smaller tumors and have their tumors detected by mammography rather than physical exam. However, hormone therapy after surgery wipes out any difference in tumor size or detection method.
Researchers have found that patients with hereditary ovarian cancer are more likely to experience secondary tumours in their liver and spleen, despite better overall prognosis. A new approach suggests testing these patients for BRCA1 and BRCA2 genes to ensure tailored treatment.
Researchers find that stress hormones can protect ovarian cancer cells from anoikis, promoting tumor growth. Higher levels of activated FAK are linked to accelerated mortality in ovarian cancer patients.
Researchers developed percutaneous soft tissue cryotherapy as an effective treatment for cancer that has metastasized in soft tissues and bones. The procedure resulted in an average of 77% tumor shrinkage in patients after 24 months, with preserved fibrous or collagenous structures promoting better healing.
A genetic signature associated with poor patient outcomes could lead to improved therapies for ovarian cancer. The study found that MAGP2, a previously unknown cancer gene, was overexpressed in tumors of patients who died more quickly.
Researchers developed nanoparticles that selectively delivered diphtheria toxin genes to ovarian cancer cells, slowing tumor growth and increasing lifespan by nearly four weeks. This therapy shows promise as a targeted treatment for advanced ovarian cancer.
Early-stage ovarian tumors can remain undetectable for years due to their small size, posing a significant challenge in early detection. The study suggests that detecting these microscopic tumors within a four-year window could enable surgeons to remove them before they spread.
Current diagnostic tests for ovarian cancer are ineffective for early detection, but a new study suggests that with improved testing, tumors can be detected up to 4.3 years before diagnosis and treatment is possible. The window of opportunity for successful treatment is surprisingly long, making reliable early detection crucial.
Researchers found a singular mutation in the FOXL2 gene that causes granulosa cell tumours, a rare and often untreatable form of ovarian cancer. The discovery provides a specific diagnostic tool and potential treatment pathway for women with this cancer type.
Research finds that increased angiogenesis and vascular endothelial growth factor expression are associated with poor survival in women with sex cord-stromal ovarian tumors. High microvessel density and VEGF overexpression were linked to significantly poorer survival rates, as well as recurrence and metastasis.
Scientists have developed a new imaging agent using bevacizumab, which surpasses existing methods in detecting tumors. The compound successfully targets cancer cells and provides clearer images of tumors, enabling earlier stages of detection and fewer false positives.
Researchers have identified a master regulator of EMT that consists of a specific group of microRNAs called miR-200. Introducing miR-200 into late cancer cells may provide a new form of treatment by preventing cells from going through EMT and becoming more invasive.
Researchers found a link between high levels of adenosine and priapism in male mice with sickle cell disease. The study suggested that reducing adenosine levels or blocking its activation could provide new treatments for priapism. Additionally, two other studies explored the development of reproductive disorders in humans and the prote...
Researchers found that low-grade serous carcinoma of the ovary is less sensitive to chemotherapy than more common high-grade ovarian cancers. The overall response rate was only 4% in patients with recurrent disease, and no response was observed in women with platinum-resistant disease.
Researchers found that combining a cancer vaccine with monoclonal antibody therapy produces strong immune responses to tumors without severe side effects. The treatment approach shows promise for refining strategies in melanoma and ovarian cancer treatment.
A study published in The Lancet Oncology found that high-quality pre-operative ultrasound examinations can significantly decrease the number of unnecessary major surgical operations on women with suspected ovarian cancer. Experts' accuracy rates were 95%, while routine operators' accuracy was lower. Increasing ultrasound expertise is k...
A new study found that experienced ultrasound examiners can accurately classify ovarian tumors using pattern recognition, outperforming blood test CA-125 levels. The method could improve diagnosis and treatment for women with ovarian cancer.
A phase II trial found that six of 17 patients with metastatic colorectal cancer showed significant tumor shrinkage after receiving the therapeutic vaccine TroVax. The study demonstrated the safety and immunogenicity of the vaccine, suggesting its potential as an immuno-therapy approach to enhance the immune response to tumors.
A study of 132 rare ovarian cancer survivors found that most retained menstrual function and reproductive ability after treatment. Despite reproductive concerns, survivors were more likely to be in meaningful, positive relationships than healthy counterparts.
A recent study has found that the gene p53, which is thought to assist chemotherapy in killing cancer cells, may actually help them thrive. In contrast, patients with normal p53 had only a 30% survival rate after five years. The research suggests that inhibiting p53 in tumors during chemotherapy could improve patients' long-term survival.
A team of researchers has identified more than 70 markers unique to ovarian tumor blood vessels, which could lead to new screening and treatment tools. The finding suggests that these markers may be a sign of an aggressive tumor and could help inform treatment decisions.
A new mouse model of non-small cell lung cancer validates MEK inhibitors as a potential treatment option. The model, developed by Dr. Martin McMahon and colleagues, shows that MEK inhibition can halt tumor progression in early-stage lung tumors.
A significant association was found between higher red meat consumption and an increased risk of hormone receptor–positive breast cancer in premenopausal women. Women who consumed more than one and one-half servings of red meat per day had almost double the risk compared to those who ate three or fewer servings per week.
A preclinical study by the University of Texas M. D. Anderson Cancer Center found that chronic stress hormones stimulate tumor growth and spread in mice with ovarian cancer. Reducing stress using a medication commonly prescribed for heart disease slows tumor growth.
Researchers have identified specific types of cancers that peak in incidence among teenagers and young adults, shedding light on potential causes. Infections, adolescent growth spurts, and hormonal factors are thought to contribute to the development of these cancers, with further research needed for conclusive evidence.
Researchers at the University of Liverpool have identified a new gene, S100P, that causes the rapid spread of cancerous cells. The discovery builds on previous findings and aims to develop drugs that can switch off the action of metastasis-inducing genes.
A study of 360 women with borderline ovarian tumours found that conservative surgery can preserve fertility, especially for younger women with unilateral BOT. However, the recurrence rate was high at 16.6% over an average 70-month period.
Strong social attachments are associated with lower IL-6 levels, reduced mortality risk, and better quality of life among women with advanced ovarian cancer. Women with weak social connections have higher IL-6 levels, which promotes tumor growth and disease progression.
A study of 2,987 female registered nurses found that higher levels of physical activity after a breast cancer diagnosis were linked to longer survival. The adjusted relative risk of death from breast cancer was 20-50% lower for women engaging in more than 3 MET-hours per week of physical activity.
A study by Fox Chase Cancer Center researchers identified a subset of ovarian cancer patients who respond to Iressa, a targeted therapy. The team found that mutations in the EGFR tyrosine kinase portion of the receptor can make tumors more susceptible to the drug, potentially leading to improved treatment outcomes for some patients.
Researchers at Newcastle University tested a cancer virotherapy on two patients with advanced melanoma, finding no systemic toxic effects. The administration of CVA21 virus directly into cancerous tumors was well-tolerated and showed promise in controlling the spread of melanoma.
A study found that highly dense breasts are associated with a higher risk of second breast cancer in women who have had ductal carcinoma in situ. Women with dense breast tissue also face a greater risk of invasive and ipsilateral breast cancer.
In a breakthrough study, researchers found that dendritic cells, a type of immune cell, can be co-opted by tumors to promote angiogenesis and tumor growth. The study suggests a new approach to fighting solid tumors by targeting the interaction between angiogenesis and the immune response.
Researchers found that ovarian cancer tumors lack response to antiestrogens due to decreased ER beta expression, which can lead to increased cell proliferation and apoptosis. The reintroduction of ER beta in cancer cells induced apoptosis, suggesting its regulatory functions in controlling ovarian cancer growth and motility.